• 1
    Biswas, S. K. and Mantovani, A., Macrophage plasticity and interaction with lymphocyte subsets: cancer as a paradigm. Nat. Immunol. 2010. 11: 889896.
  • 2
    Gabrilovich, D. I. and Nagaraj, S., Myeloid-derived suppressor cells as regulators of the immune system. Nat. Rev. Immunol. 2009. 9: 162174.
  • 3
    Bronte, V., Myeloid-derived suppressor cells in inflammation: uncovering cell subsets with enhanced immunosuppressive functions. Eur. J. Immunol. 2009. 39: 26702672.
  • 4
    Sinha, P., Clements, V. K., Bunt, S. K., Albelda, S. M. and Ostrand-Rosenberg, S., Cross-talk between myeloid-derived suppressor cells and macrophages subverts tumor immunity toward a type 2 response. J. Immunol. 2007. 179: 977983.
  • 5
    Sica, A. and Bronte, V., Altered macrophage differentiation and immune dysfunction in tumor development. J. Clin. Invest. 2007. 117: 11551166.
  • 6
    Hegde, V. L., Nagarkatti, M. and Nagarkatti, P. S., Cannabinoid receptor activation leads to massive mobilization of myeloid-derived suppressor cells with potent immunosuppressive properties. Eur. J. Immunol. 2010. 40: 33583371.
  • 7
    Elkabets, M., Ribeiro, V. S. G., Dinarello, C. A., Ostrand-Rosemberg, S., Di Santo, J. P., Apte, R. N. and Vosshenrich, C. A. J., IL-1beta regulates a novel myeloid-derived suppressor cell subset that impairs NK cell development and function. Eur. J. Immunol. 2010. 40: 33473357.
  • 8
    Marigo, I., Bosio, E., Solito, S., Mesa, C., Fernandez, A., Dolcetti, L., Ugel, S. et al., Tumor-induced tolerance and immune suppression depend on the C/EBPbeta transcription factor. Immunity 2010. 32: 790802.
  • 9
    Stewart, T. J., Liewehr, D. J., Steinberg, S. M., Greeneltch, K. M. and Abrams, S. I., Modulating the expression of IFN regulatory factor 8 alters the protumorigenic behavior of CD11b+Gr-1+ myeloid cells. J. Immunol. 2009. 183: 117128.
  • 10
    Kujawski, M., Kortylewski, M., Lee, H., Herrmann, A., Kay, H. and Yu, H., Stat3 mediates myeloid cell-dependent tumor angiogenesis in mice. J. Clin. Invest. 2008. 118: 33673377.
  • 11
    Apolloni, E., Bronte, V., Mazzoni, A., Serafini, P., Cabrelle, A., Segal, D. M., Young, H. A. and Zanovello, P., Immortalized myeloid suppressor cells trigger apoptosis in antigen-activated T lymphocytes. J. Immunol. 2000. 165: 67236730.
  • 12
    Gabrilovich, D., Ishida, T., Oyama, T., Ran, S., Kravtsov, V., Nadaf, S. and Carbone, D. P., Vascular endothelial growth factor inhibits the development of dendritic cells and dramatically affects the differentiation of multiple hematopoietic lineages in vivo. Blood 1998. 92: 41504166.
  • 13
    Ochoa, A. C., Zea, A. H., Hernandez, C. and Rodriguez, P. C., Arginase, prostaglandins, and myeloid-derived suppressor cells in renal cell carcinoma. Clin. Cancer Res. 2007. 13: 721s726s.
  • 14
    Sinha, P., Clements, V. K., Fulton, A. M. and Ostrand-Rosenberg, S., Prostaglandin E2 promotes tumor progression by inducing myeloid-derived suppressor cells. Cancer Res. 2007. 67: 45074513.
  • 15
    Song, X., Krelin, Y., Dvorkin, T., Bjorkdahl, O., Segal, S., Dinarello, C. A., Voronov, E., and Apte, R. N., CD11b+/Gr-1+ immature myeloid cells mediate suppression of T cells in mice bearing tumors of IL-1beta-secreting cells. J. Immunol. 2005. 175: 82008208.
  • 16
    Bunt, S. K., Yang, L., Sinha, P., Clements, V. K., Leips, J. and Ostrand-Rosenberg, S., Reduced inflammation in the tumor microenvironment delays the accumulation of myeloid-derived suppressor cells and limits tumor progression. Cancer Res. 2007. 67: 1001910026.
  • 17
    Marrache, F., Tu, S. P., Bhagat, G., Pendyala, S., Osterreicher, C. H., Gordon, S., Ramanathan, V. et al., Overexpression of interleukin-1beta in the murine pancreas results in chronic pancreatitis. Gastroenterology 2008. 135: 12771287.
  • 18
    Tu, S., Bhagat, G., Cui, G., Takaishi, S., Kurt-Jones, E. A., Rickman, B., Betz, K. S. et al., Overexpression of interleukin-1beta induces gastric inflammation and cancer and mobilizes myeloid-derived suppressor cells in mice. Cancer Cell 2008. 14: 408419.
  • 19
    Zhang, Y., Liu, Q., Zhang, M., Yu, Y., Liu, X. and Cao, X., Fas signal promotes lung cancer growth by recruiting myeloid-derived suppressor cells via cancer cell-derived PGE2. J. Immunol. 2009. 182: 38013808.
  • 20
    Mantovani, A., Allavena, P., Sica, A. and Balkwill, F., Cancer-related inflammation. Nature 2008. 454: 436444.
  • 21
    Garlanda, C., Anders, H. J. and Mantovani, A., TIR8/SIGIRR: an IL-1R/TLR family member with regulatory functions in inflammation and T cell polarization. Trends Immunol. 2009. 30: 439446.
  • 22
    Dinarello, C. A., Immunological and inflammatory functions of the interleukin-1 family. Annu. Rev. Immunol. 2009. 27: 519550.
  • 23
    Priceman, S. J., Sung, J. L., Shaposhnik, Z., Burton, J. B., Torres-Collado, A. X., Moughon, D. L., Johnson, M. et al., Targeting distinct tumor-infiltrating myeloid cells by inhibiting CSF-1 receptor: combating tumor evasion of antiangiogenic therapy. Blood 2010. 115: 14611471.
  • 24
    Movahedi, K., Guilliams, M., Van den Bossche, J., Van den Bergh, R., Gysemans, C., Beschin, A., De Baetselier, P. and Van Ginderachter, J. A., Identification of discrete tumor-induced myeloid-derived suppressor cell subpopulations with distinct T cell-suppressive activity. Blood 2008. 111: 42334244.
  • 25
    Rodriguez, P. C., Ernstoff, M. S., Hernandez, C., Atkins, M., Zabaleta, J., Sierra, R. and Ochoa, A. C., Arginase I-producing myeloid-derived suppressor cells in renal cell carcinoma are a subpopulation of activated granulocytes. Cancer Res. 2009. 69: 15531560.
  • 26
    Yang, C.-W., Strong, B. S. I., Miller, M. J. and Unanue, E. R., Neutrophils influence the level of antigen presentation during the immune response to protein antigens in adjuvants. J. Immunol. 2010. 185: 29272934.
  • 27
    Cassatella, M. A., Locati, M. and Mantovani, A., Never underestimate the power of a neutrophil. Immunity 2009. 31: 698700.
  • 28
    Fridlender, Z. G., Sun, J., Kim, S., Kapoor, V., Cheng, G., Ling, L., Worthen, G. S. and Alberlda, S. M., Polarization of tumor-associated neutrophil (TAN) phenotype by TGF-beta: “N1” versus “N2” TAN – a new paradigm? Cancer Cell 2009 16: 183194.
  • 29
    Movahedi, K., Laoui, D., Gysemans, C., Baeten, M., Stange, G., Van den Bossche, J., Mack, M. et al., Different tumor microenvironments contain functionally distinct subsets of macrophages derived from Ly6C(high) monocytes. Cancer Res. 2010. 70: 57285739.
  • 30
    Li, H., Han, Y., Guo, Q., Zhang, M. and Cao, X., Cancer-expanded myeloid-derived suppressor cells induce anergy of NK cells through membrane-bound TGF-beta 1. J. Immunol. 2009. 182: 240249.
  • 31
    Greifenberg, V., Ribechini, E., Rossner, S. and Lutz, M. B., Myeloid-derived suppressor cell activation by combined LPS and IFN-gamma treatment impairs DC development. Eur. J. Immunol. 2009. 39: 28652876.
  • 32
    Nausch, N., Galani, I. E., Schlecker, E. and Cerwenka, A., Mononuclear myeloid-derived “suppressor” cells express RAE-1 and activate natural killer cells. Blood 2008. 112: 40804089.
  • 33
    Bellora, F., Castriconi, R., Dondero, A., Reggiardo, G., Moretta, L., Mantovani, A., Moretta, A. and Bottino, C., Human natural killer cells and unpolarized or polarized macrophages: molecular interactions and differences in functional outcome. Proc. Natl. Sci. USA 2010. In press.
  • 34
    Kodumudi, K. N., Woan, K., Gilvary, D. L., Sahakian, E., Wei, S. and Djeu, J. Y., A novel chemoimmunomodulating property of docetaxel: suppression of myeloid-derived suppressor cells in tumor bearers. Clin. Cancer Res. 2010. 16: 45834594.
  • 35
    Suzuki, E., Kapoor, V., Jassar, A. S., Kaiser, L. R. and Albelda, S. M., Gemcitabine selectively eliminates splenic Gr-1+/CD11b+ myeloid suppressor cells in tumor-bearing animals and enhances antitumor immune activity. Clin. Cancer Res. 2005. 11: 67136721.
  • 36
    Le, H. K., Graham, L., Cha, E., Morales, J. K., Manjili, M. H. and Bear, H. D., Gemcitabine directly inhibits myeloid derived suppressor cells in BALB/c mice bearing 4T1 mammary carcinoma and augments expansion of T cells from tumor-bearing mice. Int. Immunopharmacol. 2009. 9: 900909.
  • 37
    Ko, J. S., Zea, A. H., Rini, B. I., Ireland, J. L., Elson, P., Cohen, P., Golshayan, A. et al., Sunitinib mediates reversal of myeloid-derived suppressor cell accumulation in renal cell carcinoma patients. Clin. Cancer Res. 2009. 15: 21482157.
  • 38
    Ko, J. S., Rayman, P., Ireland, J., Swaidani, S., Li, G., Bunting, K. D., Rini, B. et al., Direct and differential suppression of myeloid-derived suppressor cell subsets by sunitinib is compartmentally constrained. Cancer Res. 2010. 70: 35263536.
  • 39
    Mantovani, A., Polentarutti, N., Luini, W., Peri, G. and Spreafico, F., Role of host defense mechanisms in the antitumor activity of adriamycin and daunomycin in mice. J. Natl. Cancer Inst. 1979. 63: 6166.
  • 40
    Mantovani, A., From phagocyte diversity and activation to probiotics: back to Metchnikoff. Eur. J. Immunol. 2008. 38: 32693273.